Preview

Рецепт

Расширенный поиск

Магнийсодержащие лекарственные препараты: от клинической фармакологии до фармацевтического консультирования (часть 1)

https://doi.org/10.34883/PI.2021.24.1.005

Полный текст:

Аннотация

Магний является незаменимым катионом организма человека и содержится преимущественно в костях, мышцах и мягких тканях. Магнийсодержащие лекарственные препараты назначаются с учетом клинических и лабораторно-диагностических показателей. В статье уделено внимание биологической роли магния и связанным с ним фармакодинамическим эффектам лекарственных препаратов. Систематизирована информация по показаниям к применению и противопоказаниям, нежелательным реакциям и лекарственным взаимодействиям с позиции причинно-следственных связей, опирающихся на биохимические, фармакодинамические и фармакокинетические особенности соединений магния. Установлено, что соли магния обладают низкой биодоступностью (и зависят от типа соли), всасываются в тонком кишечнике двумя транспортными путями (параклеточный и трансклеточный), а почки оказывают важную роль в поддержании гомеостаза магния.

Об авторе

А. А. Кирилюк
РУП «БЕЛФАРМАЦИЯ»
Беларусь


Список литературы

1. Ross W.R., Preedy V.R., Sherma Z. (Eds.) (2013) Magnesium in human health and disease, USA: Springer Science+Business Media, Humana Press.

2. Helmenstine, A.M. (2019) Magnesium Facts (Mg or Atomic Number 12). Mode of access: https://www.thoughtco.com/magnesium-facts-606556. Date of access: 28.08.2020.

3. PubMed // National Center for Biotechnology Information [Electronic resource]. Mode of access: https://pubmed.ncbi.nlm.nih.gov. Date of access: 28.06.2020.

4. Reyestry UP Tsentr ekspertiz i ispytaniy v zdravookhranenii [Register of the UE Center for expertise and testing in healthcare] [Electronic resource]. Access mode: http://www.rceth.by. – Date of access: 12.10.2020.

5. Find Drugs & Conditions. Drugs.com [Electronic resource]. Mode of access: https://www.drugs.com. Date of access: 28.08.2020.

6. Whittlesea C., Hodson K. (2019) Clinical pharmacy and therapeutics, UК: Elsevier.

7. DiPiro J., Talbert R., Yee G., Matzke G., Wells B., Michael Posey L. (2016) Pharmacotherapy: a pathophysiologic approach, USA: McGraw-Hill Education.

8. Kass L. (2017) Magnesium: supplementation, absorption and effect on blood pressure and exercise [University of Exeter as a thesis for the degree of PhD]. Sport and Health Sciences.

9. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine (1997) Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. USA: National Academy Press.

10. Chisholm-Burns M., Schwinghammer T., Wells B., Malone P., DiPiro J., Kolesar J., Katz M., Matthias K. (2016) Pharmacotherapy Principles & Practice, USA: McGraw-Hill Education.

11. Ritter J., Lewis L., Mant T., Ferro A. (2008) A textbook of clinical pharmacology and therapeutics, UK: Hodder Arnold.

12. Katzung B.G. (2018) Basic & Clinical Pharmacology, USA: McGraw-Hill Education.

13. Lerchenfeldt S., Rosenfeld G. (2020) BRS Pharmacology. USA: Wolter Kluwer.

14. Papadakis M., McPhee S., Rabow M. (2019) CURRENT Medical Diagnosis & Treatment. USA: McGraw-Hill Education.

15. Zhang Y., Xun P., Wang R., Mao L., He K. (2017) Can Magnesium Enhance Exercise Performance? Nutrients, vol. 9(9), pp. 946.

16. Weiner C.P., Mason C. (2019) Drugs for pregnant and lactating women, USA: Elsevier Inc.

17. Wells B., DiPiro J., Schwinghammer T., DiPiro C. (2015) Pharmacotherapy Handbook, USA: McGraw-Hill Education.

18. ATC/DDD Index 2020. WHO Collaborating Centre for Drug Statistics Methodology [Electronic resource]. Mode of access: https://www.whocc.no/ atc_ddd_index. Date of access: 27.08.2020.

19. Petrov V.I. (2011) Klinicheskaya farmakologiya i farmakoterapiya v real`noj vrachebnoj praktike: master-klass: uchebnik [Clinical pharmacology and pharmacotherapy in real medical practice: master class: textbook]. Moskva: Geotar-Media. (in Russian)

20. Vdovichenko V.P. (2014) Farmakologiya i farmakoterapiya: Posobiye dlya vrachey [Pharmacology and pharmacotherapy: manual for doctors]. Minsk: Donarit. (in Russian)

21. Wecker L., Taylor D.A., Theobald R.J. (2019) Brody’s Human Pharmacology: Mechanism-based therapeutics, USA: Elsevier Inc.

22. Oddie S., Tuffnell D.J., McGuire W. (2015) Antenatal magnesium sulfate: neuro-protection for preterm infants. Arch Dis Child Fetal Neonatal Ed.,no 100(6), pp. F553–557.

23. Classen H.G. (2004) Magnesium orotate - experimental and clinical evidence. Rom J Intern Med., no 42 (3), pp. 491–501.

24. Zeana C. (1999) Magnesium orotate in myocardial and neuronal protection. Rom J Intern Med., no 37(1), pp. 91–97.

25. Bac P., Pages N., Herrenknecht C., Teste J.F. (1995) Inhibition of mouse-killing behaviour in magnesium-deficient rats: effect of pharmacological doses of magnesium pidolate, magnesium aspartate, magnesium lactate, magnesium gluconate and magnesium chloride. Magnes Res., no 8(1), pp. 37–45.

26. Teste J.F., Decelle T., Henrotte J.G. (1995) Propriétés psychopharmacologiques de trois sels de magnésium: pidolate, lactate et aspartate [Psychopharmacological properties of three magnesium salts: pidolate, lactate and aspartate]. Ann Pharm Fr., no 53(4), pp. 176–183.

27. Gromova O.A., Torshin I.Yu., Kalacheva A.G., Fedotova L.E., Rudakov K.V. (2016) Molekulyarnye mekhanizmy deistviya pidolata magniya i ego neirotropnye effekty [Molecular mechanisms of pidolate magnesium action and its neurotropic effects]. Zh Nevrol Psikhiatr Im S.S. Korsakova, no 116(12), pp. 96–103. (in Russian)

28. Farruggia G., Castiglioni S., Sargenti A., Marraccini C., Cazzaniga A., Merolle L., Iotti S., Cappadone C., Maier J.A. (2014) Effects of supplementation with different Mg salts in cells: is there a clue? Magnes Res, no 27(1), pp. 25–34.

29. Spasov A.A., Iezhitsa I.N., Zhuravleva N.V., Sinolitsky M.K., Voronin S.P. (2006) Comparative study of the antiarrhythmic activity of magnesium aspartate L-, D- and DL-aspartate stereoisomers. Kardiologiia, vol. 46(7), pp. 62–65. (in Russian)

30. Spasov A.A., Ozerov A.A., Iezhitsa I.N., Kharitonova M.V., Kravchenko M.S., Zheltova A.A. (2011) Correction of furosemide-induced magnesium deficiency with different stereoisomers of organic magnesium salts: a comparative study. Bull Exp Biol Med., no 151(3), pp. 333–335.

31. Uysal N., Kizildag S., Yuce Z., Guvendi G., Kandis S., Koc B., Karakilic A., Camsari U.M., Ates M. (2019) Timeline (bioavailability) of magnesium compounds in hours: Which magnesium compound works best? Biol Trace Elem Res., no 187(1), pp. 128–136.

32. Lindberg J.S., Zobitz M.M., Poindexter J.R., Pak C.Y. (1990) Magnesium bioavailability from magnesium citrate and magnesium oxide. J Am Coll Nutr., no 9(1), pp. 48–55.

33. Werner T., Kolisek M., Vormann J., Pilchova I., Grendar M., Struharnanska E., Cibulka M. (2019) Assessment of bioavailability of Mg from Mg citrate and Mg oxide by measuring urinary excretion in Mg-saturated subjects. Magnes Res., no 32(3), pp. 63–71.

34. Okusanya B.O., Oladapo O.T., Long Q., Lumbiganon P., Carroli G., Qureshi Z., Duley L., Souza J.P., Gülmezoglu A.M. (2016) Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia. BJOG, no 123(3), pp. 356–366.

35. Drogovoz S.M. (2007) Farmakologiya na ladonyax [Pharmacology on the palms]. Kharkiv: National Pharmaceutical University.

36. Rower J.E., Liu X., Yu T., Mundorff M., Sherwin C.M., Johnson M.D. (2017) Clinical pharmacokinetics of magnesium sulfate in the treatment of children with severe acute asthma. Eur J Clin Pharmacol, no 73(3), pp. 325–331.

37. Bennett P.N., Brown M.J., Sharma P. (2012) Clinical pharmacology, UК: Elsevier.

38. Kubynin A. (2012) Preparaty` kaliya i magniya v povsednevnoj klinicheskoj praktike [Potassium and magnesium supplements in daily clinical practice]. Vrach, no 6, pp. 68–72. (in Russian)

39. Shcherbakova N.I., Khrushcheva N.A., Suponeva N.A., Antonova K.V., Belova N.V., Shvedkov V.V., Shabalina A.A., Kostyreva M.V., Galkina O.I., Rudnichenko V.A., Kasatkina L.F. (2017) Preparaty`, protivopokazanny`e pri miastenii. Klinicheskie nablyudeniya manifestacii skry`ty`x form miastenii posle primeneniya D-penicillamina, timolola, sul`fata magniya, botulinicheskogo toksina tipa A, merkazolila [Medicines that are contraindicated in myasthenia gravis. A case report of latent forms of myasthenia gravis manifestation after d-penicillamine, timolol, magnesium sulfate, botulinum toxin a, mercazolilum administration]. Nevrologicheskij zhurnal, no 3, pp. 112–121.

40. Gromova O.A., Kalacheva A.G., Torshin I.Yu., Grishina T.R., Yudina N.V. (2013) Kalijsberegayushhie svojstva magniya [Potassium-preserving properties of magnesium]. Kardiologiya, no 10, pp. 38–48.

41. Johnson W.Jr., Bergfeld W.F., Belsito D.V., Hill R.A., Klaassen C.D., Liebler D.C., Marks J.G. Jr., Shank R.C., Slaga T.J., Snyder P.W., Andersen F.A., Heldreth B. (2018) Safety assessment of magnesium sulfate as used in cosmetics. Int J Toxicol., no 37(1), pp. 47–54.

42. Oddie S., Tuffnell D.J., McGuire W. (2015) Antenatal magnesium sulfate: neuro-protection for preterm infants. Arch Dis Child Fetal Neonatal Ed., no 100(6), pp. F553–557.


Для цитирования:


Кирилюк А.А. Магнийсодержащие лекарственные препараты: от клинической фармакологии до фармацевтического консультирования (часть 1). Рецепт. 2021;(1):49-66. https://doi.org/10.34883/PI.2021.24.1.005

For citation:


Kirilyuk .A. Magnesium-Containing Medicines: from Clinical Pharmacology to Pharmaceutical Assistance (Part 1). Recipe. 2021;(1):49-66. (In Russ.) https://doi.org/10.34883/PI.2021.24.1.005

Просмотров: 13


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1993-4882 (Print)
ISSN 2414-2263 (Online)